Last $2.55 USD
Change Today -0.04 / -1.54%
Volume 872.2K
CTIC On Other Exchanges
Symbol
Exchange
BrsaItaliana
NASDAQ CM
Frankfurt
As of 8:10 PM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

cti biopharma corp (CTIC) Snapshot

Open
$2.60
Previous Close
$2.59
Day High
$2.62
Day Low
$2.55
52 Week High
01/21/14 - $4.25
52 Week Low
08/7/13 - $1.01
Market Cap
382.5M
Average Volume 10 Days
1.3M
EPS TTM
$-0.49
Shares Outstanding
150.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CTI BIOPHARMA CORP (CTIC)

Related News

No related news articles were found.

cti biopharma corp (CTIC) Related Businessweek News

No Related Businessweek News Found

cti biopharma corp (CTIC) Details

CTI BioPharma Corp., a biopharmaceutical company, is engaged in the acquisition, development, and commercialization of treatments for cancer. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative, which is in phase III clinical trials for the treatment of multiply relapsed or refractory aggressive non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an oral inhibitor of Janus Kinase 2 and FMS-like tyrosine kinase, which is in phase III clinical trials for the treatment of myelofibrosis; and is in phase II clinical trial for treatment of relapsed acute myeloid leukemia. In addition, it is developing Tosedostat, an oral aminopeptidase inhibitor that is in phase II clinical trials for the treatment of acute myeloid leukemia; and is in phase II clinical trials for the treatment of acute myeloid leukemia/myelodysplastic syndrome. Further, the company is developing Opaxio, a chemotherapeutic agent that is in phase III clinical trials for the treatment of ovarian cancer; in phase II clinical trials for the treatment of malignant brain cancer; and is in phase II clinical trials for the treatment of head and neck cancer. Additionally, it is developing Brostallicin, which is in phase II clinical trials for the treatment of triple-negative breast cancer. The company has a license and co-development agreement with Chroma Therapeutics, Ltd. to develop and commercialize Tosedostat in North, Central, and South America, or the licensed territory; and a development, commercialization, and license agreement with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA to develop and commercialize Pacritinib worldwide. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

111 Employees
Last Reported Date: 03/4/14
Founded in 1991

cti biopharma corp (CTIC) Top Compensated Officers

Principal Founder, Chief Executive Officer, P...
Total Annual Compensation: $1.3M
Co-Founder, Principal Financial Officer, Prin...
Total Annual Compensation: $553.5K
Co-Founder, Chief Compliance Officer, Interim...
Total Annual Compensation: $551.0K
Executive Vice President of Corporate Develop...
Total Annual Compensation: $585.0K
Compensation as of Fiscal Year 2013.

cti biopharma corp (CTIC) Key Developments

CTI Biopharma Corp. Receives Approval from the Israeli Ministry of Health for PIXUVRI

CTI BioPharma Corp. announced that it has received approval from the Israeli Ministry of Health (MOH) for PIXUVRI (pixantrone). PIXUVRI in Israel is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL) who have received not more than three previous courses of treatment. The benefit of pixantrone treatment has not been established in patients when used as fifth line or greater chemotherapy in patients who are refractory to last therapy. In Israel, PIXUVRI will be distributed and marketed by the Neopharm Group. Separately, the Dutch Healthcare Authority (NZa) and the healthcare insurance board College voor zorgverzekeringen (CVZ) of the Netherlands have approved funding for PIXUVRI as an add-on drug for patients who need a third- or fourth-line treatment option for aggressive B-cell lymphoma. This follows the inclusion of PIXUVRI on the HOVON (Haemato Oncology Foundation for Adults in the Netherlands) treatment guidelines, effective June 1, 2014. The inclusion on the Dutch list of reimbursed drugs makes PIXUVRI the first registered and reimbursed medicine for the treatment of patients with multiply relapsed or refractory aggressive B-cell NHL in the Netherlands.

CTI BioPharma Corp. Completes Recruitment in PERSIST-1 Pivotal Phase 3 Trial of Pacritinib for Patients with Myelofibrosis

CTI BioPharma Corp. announced that it has completed recruitment in the PERSIST-1 pivotal Phase 3 clinical trial of pacritinib, a novel oral JAK2/FLT3 inhibitor that is being evaluated for the treatment of myelofibrosis. Under the development and commercialization agreement for pacritinib with Baxter International Inc. (Baxter), CTI expects to receive a $20 million development milestone payment in connection with the first treatment dosing of the last patient enrolled in PERSIST-1. CTI expects to achieve this milestone and receive payment by mid-third quarter 2014. The PERSIST-1 trial is the first of two Phase 3 trials in the pacritinib development program in myelofibrosis. The second Phase 3 trial, PERSIST-2, is currently evaluating pacritinib for the treatment of patients with low platelet counts compared to best available therapy, including approved JAK2 inhibitors at their recommended dose and schedule for myelofibrosis patients with thrombocytopenia. The two clinical trials are intended to support an anticipated New Drug Application (NDA) regulatory submission in the U.S. in late 2015, followed by an anticipated Marketing Authorization Application (MAA) in Europe in 2016. The PERSIST-1 trial was designed to enroll approximately 320 patients and is a randomized, open-label, multicenter trial comparing the efficacy and safety of pacritinib with that of best available therapy, other than JAK inhibitors, in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, without exclusion for low platelet counts. The primary endpoint is the percentage of patients achieving a greater than or equal to 35% reduction in spleen volume measured by MRI or CT at 24 weeks of treatment.

CTI BioPharma Corp. Presents at ROTH Healthcare Corporate Access Day - London, Jun-24-2014

CTI BioPharma Corp. Presents at ROTH Healthcare Corporate Access Day - London, Jun-24-2014 . Venue: The Dorchester, 3 Tilney Street, London, W1K 1BJ, United Kingdom.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CTIC:US $2.55 USD -0.04

CTIC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $4.07 USD -0.11
Curis Inc $1.77 USD -0.03
Cytokinetics Inc $4.11 USD -0.13
Progenics Pharmaceuticals Inc $4.99 USD -0.09
Rigel Pharmaceuticals Inc $3.27 USD -0.05
View Industry Companies
 

Industry Analysis

CTIC

Industry Average

Valuation CTIC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.5x
Price/Book 14.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CTI BIOPHARMA CORP, please visit www.ctibiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.